Galectin Therapeutics Inc. (the Company) announced that it has appointed Pol F. Boudes, M.D., as the Chief Medical Officer of the Company, with an initial term to commence on March 2, 2020. Prior to joining the Company, Dr. Boudes served as the Chief Medical Officer of CymaBay Therapeutics Following this experience, Dr. Boudes became a Board member of Protalix BioTherapeutics. Dr. Boudes will serve as the Chief Medical Officer of the Company during an initial term that commences on March 2, 2020 and expires on February 28, 2021.